Kisqali 400 MG daily dose 42S
Ended Awarded Last action
- Contract number
- SPE2DR26F7UD3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,139
Award facts
- Contract value 100% obligated
- $18,138.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Kisqali 400 mg daily dose tablets (42-unit quantity) under a firm fixed-price contract valued at $18,138.76. The award was made on December 1, 2025, with an ultimate completion date of December 22, 2025. This delivery order represents a competitively awarded contract with no set-aside designation, issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 billion and extending through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania.
As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a broad range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Kisqali is a specialty oncology medication used in breast cancer treatment, reflecting the company's role in delivering specialized pharmaceutical products across multiple therapeutic domains. This delivery order exemplifies the routine execution of AmerisourceBergen's prime indefinite delivery contract with DLA, which enables flexible and responsive pharmaceutical supply to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Quick answers
Who was awarded contract SPE2DR26F7UD3?
SPE2DR26F7UD3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26F7UD3 worth?
The government has obligated $18,139 on SPE2DR26F7UD3.
Is contract SPE2DR26F7UD3 an order under another contract?
Yes. SPE2DR26F7UD3 is a delivery order under SPE2DR25D2216, an indefinite delivery contract.
Was contract SPE2DR26F7UD3 competed?
The extent of competition for SPE2DR26F7UD3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award